Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;27(7):1210-1223.
doi: 10.1111/ene.14221. Epub 2020 Apr 24.

Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease

D Santos-García  1 , T de Deus Fonticoba  2 , E Suárez Castro  2 , A Aneiros Díaz  2 , D McAfee  3 , M J Catalán  4 , F Alonso-Frech  4 , C Villanueva  4 , S Jesús  5 , P Mir  5 , M Aguilar  6 , P Pastor  6 , J García Caldentey  7 , E Esltelrich Peyret  7 , L L Planellas  8 , M J Martí  8 , N Caballol  9 , J Hernández Vara  10 , G Martí Andrés  11 , I Cabo  12 , M A Ávila Rivera  13 , L López Manzanares  14 , N Redondo  14 , P Martinez-Martin  15 ; COPPADIS Study Group; D McAfee
Collaborators, Affiliations

Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease

D Santos-García et al. Eur J Neurol. 2020 Jul.

Abstract

Background and purpose: The objective of this study was to analyze the relationship between motor complications and non-motor symptom (NMS) burden in a population of patients with Parkinson's disease (PD) and also in a subgroup of patients with early PD.

Methods: Patients with PD from the COPPADIS cohort were included in this cross-sectional study. NMS burden was defined according to the Non-Motor Symptoms Scale (NMSS) total score. Unified Parkinson's Disease Rating Scale (UPDRS) part IV was used to establish motor complication types and their severity. Patients with ≤5 years of symptoms from onset were included as patients with early PD.

Results: Of 690 patients with PD (62.6 ± 8.9 years old, 60.1% males), 33.9% and 18.1% presented motor fluctuations and dyskinesia, respectively. The NMS total score was higher in patients with motor fluctuations (59.2 ± 43.1 vs. 38.3 ± 33.1; P < 0.0001) and dyskinesia (63.5 ± 40.7 vs. 41.4 ± 36.3; P < 0.0001). In a multiple linear regression model and after adjustment for age, sex, disease duration, Hoehn & Yahr stage, UPDRS-III score and levodopa equivalent daily dose, UPDRS-IV score was significantly related to a higher NMSS total score (β = 0.27; 95% confidence intervals, 2.81-5.61; P < 0.0001), as it was in a logistic regression model on dichotomous NMSS total score (≤40, mild or moderate vs. >40, severe or very severe) (odds ratio, 1.31; 95% confidence intervals, 1.17-1.47; P < 0.0001). In the subgroup of patients with early PD (n = 396; mean disease duration 2.7 ± 1.5 years), motor fluctuations were frequent (18.1%) and similar results were obtained.

Conclusions: Motor complications were frequent and were associated with a greater NMS burden in patients with PD even during the first 5 years of disease duration.

Keywords: Parkinson’s disease; dyskinesia; fatigue; motor fluctuations; non-motor symptoms.

PubMed Disclaimer

References

    1. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson´s disease. Nat Rev Neurosci 2017; 18: 435-450.
    1. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413.
    1. Franke C, Storch A. Nonmotor fluctuations in Parkinson's disease. Int Rev Neurobiol 2017; 134: 947-971.
    1. Santos García D, Jesús S, Aguilar M, et al. COPPADIS-2015 (COhort of Patient’s with PArkinson’s DIsease in Spain, 2015): An ongoing global Parkinson’s disease project about disease progression with more than 1,000 subjects included. Results from the baseline evaluation. Eur J Neurol 2019; 26: 1399-1407.
    1. Santos-García D, Mir P, Cubo E, et al. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global - clinical evaluations, serum biomarkers, genetic studies and neuroimaging - prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurology 2016; 16: 26.

LinkOut - more resources